Unavoidable Exposures · Teenagers · Lung Health · Neurodevelopment
Vaping was sold as a safer alternative to smoking. In adults trying to quit cigarettes, that argument has some merit. In teenagers who never smoked, it is something else entirely — a nicotine delivery system marketed in flavours, sold in bright packaging, and applied to developing brains that are exquisitely vulnerable to precisely what it delivers.
My daughter is in a minority at her school. She doesn't vape. And she is researching the subject for an essay — getting ahead of the work four weeks before term starts, which tells you something about her. It has also brought the subject into our house in a way that made me want to write about it properly.
The minority position she occupies is an interesting one. In previous generations, the social pressure around substances ran in one direction: to participate was to be part of the group, to abstain was to be outside it. That dynamic hasn't changed. What has changed is the substance — and the way it's delivered, marketed, and understood by the teenagers using it.
Vaping is not cigarettes. That's the point, and the problem.
Electronic cigarettes were introduced commercially in the mid-2000s, primarily as a harm-reduction tool for existing smokers. The core argument was straightforward and largely defensible: cigarette smoke contains thousands of toxic combustion products — carbon monoxide, tar, benzene, formaldehyde, hydrogen cyanide — that are responsible for the majority of smoking-related harm. An aerosol that delivers nicotine without combustion would, in principle, be significantly less harmful.
Public Health England's 2015 review — the one that generated the "95% safer than cigarettes" headline — was referring to this comparison: vaping versus smoking, in people already addicted to nicotine, as a cessation or harm-reduction strategy. That specific claim, in that specific context, had a reasonable evidential basis.
What it was not — and what was never intended — was a statement that vaping is safe. Or that it is appropriate for people who don't smoke. Or that it is, in any meaningful sense, suitable for children.
These distinctions were lost almost immediately in the public conversation, and exploited almost immediately by an industry that saw a vast untapped market in the one demographic that conventional tobacco marketing had been legally prevented from targeting for decades: young people.
The base liquid in most vapes contains propylene glycol and vegetable glycerin — the compounds that produce the visible vapour. These are considered relatively safe in food applications. They have not been studied for long-term inhalation, which is a different route of exposure with different consequences. When heated and inhaled repeatedly across years, their effects on the respiratory epithelium and lung microbiome are genuinely unknown.
What goes into the base liquid alongside the propylene glycol and glycerin is where the clinical concern concentrates.
In 2019, the United States experienced an outbreak of severe lung injury directly attributed to vaping — termed EVALI (e-cigarette or vaping product use-associated lung injury). Over 2,800 cases were hospitalised and 68 people died. The primary culprit was vitamin E acetate used as a cutting agent in illicit THC vapes, but the outbreak was the first population-level demonstration that vaping could cause acute, serious, and potentially fatal lung injury. It also revealed how little was understood about what was actually in vape products and what happened when those compounds were inhaled at temperature.
The regulatory picture is additionally complicated by the market structure. The legal vape market — subject to the Tobacco Products Directive, nicotine limits, ingredient disclosure requirements — is not where the majority of under-18 vaping is happening. Illegal disposable vapes, often manufactured with no meaningful regulatory oversight, are the primary product in school environments. These may contain nicotine concentrations far above the legal limit, unknown flavouring chemicals, and device components not designed for safe inhalation.
The human brain is not fully developed until the mid-twenties. This is not a metaphor or a loose generalisation — it is a specific neurobiological fact with direct relevance to nicotine exposure.
The US Surgeon General's 2016 report on e-cigarette use among young people remains the most authoritative public health statement on this subject. It concluded that nicotine exposure during adolescence can harm the developing brain — which continues developing until the mid-twenties — and that nicotine can impact learning, memory, and attention in young people. The report called teenage vaping a "major public health concern" at a time when the UK regulatory framework had not yet caught up. Its findings on receptor upregulation and adolescent vulnerability have been substantially reinforced by subsequent research.
What this means practically: a 15-year-old who vapes daily for two years is not doing something equivalent to an adult smoking for two years, subsequently quitting, and returning to their previous neurological baseline. The adolescent brain's response to nicotine alters its own developmental trajectory. The upregulated receptor density, the altered prefrontal development, the established reward circuitry patterns — these are not temporary effects that resolve when the vaping stops. They are developmental changes that the brain then builds on.
For most of the history of respiratory medicine, the lungs were considered sterile. We now know this is wrong. The lungs have their own microbiome — distinct from the gut microbiome but similarly complex, similarly important, and similarly vulnerable to disruption.
Cigarette smoke causes significant and well-documented dysbiosis of the lung microbiome — shifts in bacterial community composition that are associated with increased susceptibility to respiratory infection, altered immune responses, and chronic inflammatory lung conditions. The research on vaping and the lung microbiome is less mature, because vaping is newer, but the early data is concerning.
Studies have found that vaping shifts the lung microbiome in patterns that differ from both smoking and non-smoking — not necessarily identical to cigarette-induced dysbiosis, but not neutral either. The flavouring chemicals appear to have antimicrobial properties that selectively disrupt certain bacterial populations. The particulate load and thermal byproducts create an altered airway environment that changes which microorganisms can thrive.
The consequences of lung microbiome dysbiosis in teenagers — whose respiratory immune development is still ongoing — are genuinely unknown, because we don't have the longitudinal data yet. We are, as I wrote in the fragrance piece, running a population-level experiment in real time.
The clinical picture matters. But it doesn't explain why teenagers vape, and it doesn't explain the specific pressure dynamic that my daughter is navigating and that I suspect many parents don't fully understand.
Action on Smoking and Health (ASH) publishes annual UK data on teenage vaping. Their 2024 report found that 20.5% of 11–17 year olds in Great Britain had tried vaping — up from 15.8% in 2022. Among current vapers, the majority reported using disposable vapes, and flavour was cited as the primary reason for choosing a product. The most popular flavours among under-18s were fruit and sweet/dessert profiles — precisely the categories that have since faced regulatory restriction. Regular vaping (at least weekly) among never-smokers aged 11–17 rose to 7.6% in 2024.
Previous drug problems in teenage populations involved substances that were clearly illegal, clearly stigmatised by adult society, and clearly categorised as transgressive. The social dynamic was: this is forbidden, therefore some teenagers will do it, and the ones who don't will be the ones who follow the rules or fear the consequences.
Vaping has a different social architecture. It is sold in bright colours, in dessert flavours, in packaging that deliberately echoes confectionery. Until very recently it was available in corner shops. It doesn't smell like cigarettes. It doesn't look like drug use. Adults — who grew up understanding that the visible smoke and smell of cigarettes was the signal of harm — often don't recognise what they're seeing. Teachers don't reliably catch it. Parents don't reliably see it.
This means the social prohibition signal is weak. Vaping sits in a category that teenagers can, with some justification, argue is ambiguous — not the same as smoking, not clearly as bad, not as visibly transgressive. The cultural permission structure is different.
And the specific pressure experienced by non-vapers is consequently different too. It's not the pressure of being the only person not doing something exciting and forbidden. It's the pressure of being the only person not doing something that everyone else seems to regard as unremarkable — as routine as chewing gum. The minority position is not "I'm too straight-laced for this" but "I'm the odd one out in a situation that doesn't seem to have obvious edges."
The teenager who doesn't vape isn't refusing to do something dangerous. In the social framing of their peer group, they're refusing to do something ordinary. That's a harder position to hold.
This is worth understanding as a parent, as a teacher, and as a clinician. The intervention that works for a clearly transgressive behaviour — make the consequences visible and credible — doesn't map onto a behaviour that doesn't feel transgressive to the people doing it.
There has been significant debate about whether vaping acts as a gateway to cigarette smoking. The evidence here is genuinely mixed — some studies show that teenage vapers are more likely to subsequently smoke cigarettes, others suggest the relationship is more complex than a simple gateway model implies.
But I think the gateway question, framed as "does vaping lead to cigarettes," slightly misses the more important point. Nicotine is nicotine. The gateway that matters neurologically is not vaping to cigarettes but nicotine exposure to nicotine dependence — and from nicotine dependence to an altered reward system that is subsequently more vulnerable to other addictive processes.
Nicotine dependence in teenagers increases the risk of depression, anxiety, and other substance use disorders. This is not because nicotine directly causes these things, but because the reward circuitry alterations that nicotine produces in the developing brain change the neurological substrate on which mood regulation, stress response, and subsequent substance interactions all operate.
A teenager who becomes nicotine-dependent via vaping at 14 has, neurologically, a different adolescence than one who doesn't — independent of whether they ever touch a cigarette.
It is worth pausing on how the cigarette story ended, because the pattern is instructive.
For decades, the tobacco industry knew what cigarette smoke did, suppressed the evidence, marketed directly to young people, and argued that individual freedom and personal choice should override regulatory intervention. The public health response took fifty years to fully materialise. We now consider it unthinkable to smoke in restaurants, on public transport, in offices. The ban on smoking in enclosed public spaces in the UK — Scotland first, in 2006 — is regarded as one of the most successful public health interventions of the modern era.
The vaping industry is following an identical playbook. The products are different. The harm profile is different. The timescale of evidence accumulation is different. But the industry behaviour — suppress uncertainty, market to the young, argue personal freedom, resist regulation — is recognisable to anyone who watched the tobacco story unfold.
Research published in journals including Tobacco Control and by the Truth Initiative in the US has documented systematic targeting of young people by vaping brands. Analysis of social media marketing found that vape brands disproportionately used platforms, influencers, and content formats with high under-18 audiences. Flavour naming conventions (candy floss, bubblegum, mango ice) and packaging designed to resemble confectionery were shown to be significantly more appealing to under-18s than to adult smokers. The UK's ban on disposable vapes and restrictions on flavour marketing came directly from this evidence base — and followed the same arc as restrictions on cigarette advertising decades earlier.
The regulatory response is coming. Single-use disposable vapes are being banned. Flavoured vaping products are under increasing restriction. But regulation lags the market, and in the interim, a generation of teenagers is providing the long-term safety data that would have been required before any other inhaled product was placed on the open market.
We do not yet have 20-year longitudinal data on the health consequences of teenage vaping because vaping has not existed for 20 years. By the time we do, the teenagers currently vaping will be in their thirties and forties — and will have either demonstrated or disproved the harms that the available evidence currently suggests.
The precautionary principle — acting on available evidence of risk before full proof of harm — is the appropriate framework when the population being exposed is developing, the exposure is addictive, and the long-term consequences are unknown. Waiting for certainty is not a neutral position. It is a choice to allow the experiment to continue.
This section is not aimed at parents who want to lecture their children. It's aimed at teenagers themselves — the ones like my daughter who are navigating this from the non-vaping side and want arguments that are actually useful in a social context.
The "it's bad for you" argument doesn't work, for the same reason it never worked for cigarettes with teenagers: the time horizon of the harm is too distant to feel real at 15. Nobody at 15 is genuinely motivated by what will be true at 35.
The arguments that are actually more useful:
You're paying for addiction. Nicotine dependence is not a lifestyle choice. It's a neurochemical state that the industry has engineered to be as fast-developing and as hard to reverse as possible. The first experience of craving — wanting a vape when you can't have one, feeling worse without it than you did before you started — is the moment the product is working as designed. You're not buying relaxation or social belonging. You're buying a recurring need.
The flavours are the manipulation. No adult product designed for adult consumption needs to taste like mango ice cream or bubblegum. The flavour profiles of disposable vapes are not there because adults want them. They are there because 14-year-olds want them. The packaging, the colours, the names — these are deliberate design choices made by people who know exactly who they're selling to and are betting that you won't notice.
The social pressure runs in one direction. Nobody who vapes is going to refuse to spend time with someone who doesn't. The pressure to join is real; the social consequences of not joining are not. The peer group that makes you feel odd for not vaping is a peer group that has been successfully marketed to — and the most useful thing you can do is notice that.
Vaping sits in the same category as synthetic fragrance, glyphosate, mycotoxins, and the other subjects in this series: a modern exposure whose long-term health consequences are not yet fully known, whose commercial interests drive minimisation of risk, and whose effects fall disproportionately on those least able to evaluate the evidence or resist the marketing.
The difference with teenage vaping is the deliberateness of the targeting, the speed of dependence development, and the developmental window involved. Children are not small adults. Their brains are not finished. The exposures they receive during development do not have the same consequences as equivalent exposures in maturity.
We knew this about alcohol. We knew it about cigarettes. We know it about vaping. The question is whether we act on what we know before the longitudinal data arrives — or after.
The key sources underpinning this post, for those who want to go deeper:
US Surgeon General's Report on E-Cigarette Use Among Youth and Young Adults (2016) — the foundational public health document on adolescent vaping risk. Available at surgeongeneral.gov.
ASH (Action on Smoking and Health) — Use of e-cigarettes among young people in Great Britain (2024) — annual UK prevalence data, freely available at ash.org.uk. Essential reading for the UK context.
EVALI outbreak investigation, CDC (2019–2020) — the US Centers for Disease Control documentation of the 2019 vaping lung injury outbreak. Available at cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.
Collier et al. — Nicotinic cholinergic receptors in the adolescent brain — key mechanistic research on receptor upregulation. Published in Neuropharmacology.
Truth Initiative — marketing research — extensive documentation of youth-targeted vaping marketing strategies at truthinitiative.org.
Tobacco Control journal — ongoing peer-reviewed research on e-cigarette constituents, health effects, and marketing. Accessible via pubmed.ncbi.nlm.nih.gov.
Synthetic fragrance, vaping, glyphosate, mycotoxins — the modern toxic background that conventional medicine isn't measuring. The DH Clinical Concierge can help you understand how these exposures might be affecting you specifically.
Talk to the Concierge